decisionhealth Newsletters, Part B News - 2006 Issue 7 (July)
OIG: Medicare overpays for some cancer drugs
Subscribe or sign in to view the full article.
Article Overview
This article reviews an HHS Office of the Inspector General report on Medicare payment levels for selected Part B drugs, with a focus on oncology-related medications and average sales price comparisons. It is relevant to coding, billing, compliance, and reimbursement professionals who track drug payment policy, CMS methodology, and audit findings that may affect practice revenue. The piece also notes the agency’s view of market-price stability and the potential impact of pricing differences over time.
Why This Topic Matters
Payment methodology for Medicare Part B drugs affects physician reimbursement, compliance review, and revenue forecasting, especially for practices administering oncology therapies. Understanding OIG findings helps readers monitor policy scrutiny around drug pricing and reimbursement variance.
What You Will Learn
- What the OIG report examined about Medicare Part B drug payment levels
- How oncology-related drug reimbursement was discussed in relation to market pricing
- Why CMS drug-pricing methodology and audit findings matter to providers and billing teams
- What general reimbursement concerns were raised for selected injectable drugs
Who Should Read This
- Medical coders
- Billing specialists
- Compliance professionals
- Oncology practice administrators
- Revenue cycle staff
- Healthcare auditors
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com